Esmaili Mozhgan, Jafari Narjes, Ahmadzadeh Fatemeh, Toosi Seyed Mohammad Valizadeh, Abediankenari Saeid
Immunogenetics Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Gut and Liver Research Center, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
BMC Immunol. 2025 Feb 25;26(1):9. doi: 10.1186/s12865-025-00688-6.
Cancer-associated fibroblast (CAF) cells play an important role in gastric malignancy. MiRNA dysregulation has been detected in CAF cells, which is related to the tumor progression ability of these cells. Therefore, this study aimed to evaluate the function of miRNA34a in CAF cells in gastric carcinoma.
We transiently transfected miRNA-34a mimic in CAF cells and examined the effect of the overexpressed miRNA on PD-L1 expression using real-time PCR. Next, we evaluated the role of transfected CAF-conditioned medium (CM) on the immune response and viability of gastric cancer cell lines.
We have shown that miRNA-34a significantly reduced PD-L1 expression in CAF cells (p < 0.05). However, the conditioned medium of transfected cells had no significant effect on the immune response. We also found that CM of miRNA-34a transfected CAF cells significantly suppressed gastric cancer cell line viability relative to the control group (P < 0.05).
We indicated that CM of miRNA-34a transfected CAF can reduce gastric cancer cell line proliferation. Additionally, miRNA-34a in these cells may improve immune response via PD-L1 reduction. Thus, miRNA-34a could be a potential therapeutic agent in gastric cancer treatment.
Not applicable.
癌症相关成纤维细胞(CAF)在胃癌中起重要作用。在CAF细胞中已检测到微小RNA(miRNA)失调,这与这些细胞的肿瘤进展能力有关。因此,本研究旨在评估miRNA34a在胃癌CAF细胞中的功能。
我们将miRNA - 34a模拟物瞬时转染到CAF细胞中,并使用实时PCR检测过表达的miRNA对PD - L1表达的影响。接下来,我们评估转染的CAF条件培养基(CM)对胃癌细胞系免疫反应和活力的作用。
我们发现miRNA - 34a显著降低了CAF细胞中PD - L1的表达(p < 0.05)。然而,转染细胞的条件培养基对免疫反应没有显著影响。我们还发现,相对于对照组,miRNA - 34a转染的CAF细胞的CM显著抑制了胃癌细胞系的活力(P < 0.05)。
我们表明,miRNA - 34a转染的CAF的CM可以降低胃癌细胞系的增殖。此外,这些细胞中的miRNA - 34a可能通过降低PD - L1来改善免疫反应。因此,miRNA - 34a可能是胃癌治疗中的一种潜在治疗剂。
不适用。